Eculizumab for Shiga‐toxin‐induced hemolytic uremic syndrome in adults with neurological involvement

Autor: Benjamin J. Lee, Zhaohui Arter, Jean Doh, Shawn P. Griffin, Pongthep Vittayawacharin, Steven Atallah, Kevin R. Shieh, Minh‐Ha Tran, Sonata Jodele, Piyanuch Kongtim, Stefan O. Ciurea

Publikováno v: eJHaem, Vol 5, Iss 3, Pp 548-553 (2024)

Abstract The role of eculizumab in treating Shiga‐toxin‐producing Escherichia coli (STEC) hemolytic uremic syndrome (HUS) patients with neurological involvement remains unclear. We describe two distinctly different STEC‐HUS patients with neurol

Externí odkaz: https://doaj.org/article/4bc406e7e8064859bcf876b3e1a7e21d

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Extending duration of letermovir prophylaxis in haploidentical stem cell transplantation.

Autor: Vittayawacharin P; Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of California Irvine, California, USA; Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok., Lee BJ; Department of Pharmacy, University of California Irvine Health, Orange, CA, USA; Department of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of California, Irvine, California., Griffin S; Department of Pharmacy, University of California Irvine Health, Orange, CA, USA; Department of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of California, Irvine, California., Doh J; Department of Pharmacy, University of California Irvine Health, Orange, CA, USA; Department of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of California, Irvine, California., Smith J; Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of California Irvine, California., Nam H; Division of Infectious Diseases, Department of Medicine, University of California Irvine, California., Blodget E; Division of Infectious Diseases, Department of Medicine, University of California Irvine, California., Jeyakumar D; Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of California Irvine, California., Kongtim P; Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of California Irvine, California., Ciurea SO; Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of California Irvine, California. sciurea@hs.uci.edu.

Publikováno v: Haematologica [Haematologica] 2024 Nov 01; Vol. 109 (11), pp. 3806-3810. Date of Electronic Publication: 2024 Nov 01.

ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies.

Autor: Kongtim P; Hematopoietic Stem Cell Transplant and Cellular Therapy Program, Division of Hematology and Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA, USA., Vittayawacharin P; Hematopoietic Stem Cell Transplant and Cellular Therapy Program, Division of Hematology and Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA, USA., Zou J; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Srour S; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shaffer B; Adult BMT Service, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Shapiro RM; Department of Medical Oncology, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., Varma A; Section of Bone Marrow Transplant and Cell Therapy, Division of Hematology and Oncology, University of Arkansas for Medical Sciences, Little Rock, AK, USA., McGuirk J; Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Medical Center, Kansas City, KS, USA., Dholaria BR; Vanderbilt University Medical center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA., McCurdy SR; Division of Hematology and Oncology and Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadephia, PA, USA., DeZern AE; Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA., Bejanyan N; Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA., Bashey A; BMT, Acute Leukemia and Cellular Immunotherapy Program at Northside Hospital, Blood and Marrow Transplant Group of Georgia, Atlanta, GA, USA., Furst S; Programme de Transplantation et d'Immunothérapie Cellulaire, Département d'Hématologie, Institut Paoli Calmettes, Marseille, France., Castagna L; BMT Unit, Ospedale Villa Sofia Cervello, Palermo, Italy., Mariotti J; Department of Oncology/Hematology, Humanitas Clinical and Research Center, Rozzano, Italy., Ruggeri A; Hematology and BMT unit, IRCCS San Raffaele Scientific Institute, Milano, Italy., Bailen R; Hematology and Hemotherapy Department, Gregorio Marañon University Hospital, Gregorio Marañon Health Research Institute, Madrid, Spain., Teshima T; Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan., Xiao-Jun H; Peking University Institute of Hematology, Beijing, China., Bonfim C; Pele Pequeno Principe Research institute/Faculdades Pequeno Principe, Curitiba, Brazil., Aung F; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Cao K; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Carpenter PA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Hamadani M; Medical College of Wisconsin, Milwaukee, WI, USA., Askar M; College of Medicine, Qatar University, Doha; Qatar and National Marrow Donor Program, Minneapolis, MN., Fernandez-Vina M; Department of Pathology, Stanford University, Stanford, CA, USA., Girnita A; HLA Laboratory, Department of Pathology, University of California Irvine, Irvine, CA, USA., Ciurea SO; Hematopoietic Stem Cell Transplant and Cellular Therapy Program, Division of Hematology and Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA, USA. Electronic address: sciurea@hs.uci.edu.

Publikováno v: Transplantation and cellular therapy [Transplant Cell Ther] 2024 Sep 10. Date of Electronic Publication: 2024 Sep 10.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.